Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Aucentra Therapeutics Pty Ltd
Beta Pharma Inc
Betta Pharmaceuticals Co Ltd
Cothera Bioscience Pty Ltd
CStone Pharmaceuticals Co Ltd
Eli Lilly and Co
ESSA Pharma Inc
Fochon Pharmaceutical Ltd
G1 Therapeutics Inc
Guangzhou BeBetter Medicine Technology Co Ltd
HEC Pharma Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
MEI Pharma Inc
Novartis AG
Nuvation Bio Inc
Onconova Therapeutics Inc
OnQuality Pharmaceuticals LLC
Pfizer Inc
Prelude Therapeutics Inc
Qilu Regor Therapeutics Inc
Rhizen Pharmaceuticals SA
Rizen (Suzhou) Biosciences Co Ltd
Sanofi
SATT Conectus Alsace SAS
Shanghai Haihe Biopharma Co Ltd
Shanghai Haishi Biopharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Xunhe Pharmaceutical Technology Co Ltd
Shengke Pharmaceuticals (Jiangsu) Ltd
SiglRx Pharmaceuticals Inc
Sihuan Pharmaceutical Holdings Group Ltd
Simcere Pharmaceutical Group Ltd
Sino Biopharmaceutical Ltd
Tetranov Intertiol Inc
Tizia Life Sciences Plc
Travecta Therapeutics Inc
ViroStatics SRL
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles
abemaciclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
AU-294 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AU-314 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BEBT-209 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BPI-1178 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BPI-16350 - Drug Profile
Product Description
Mechanism Of Action
History of Events
cetuximab + cobimetinib + palbociclib - Drug Profile
Product Description
Mechanism Of Action
CS-3002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
dalpiciclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drug to Inhibit CDK4 for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
ebvaciclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ETH-155008 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FCN-437c - Drug Profile
Product Description
Mechanism Of Action
History of Events
GZ-381 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HEC-80797 - Drug Profile
Product Description
Mechanism Of Action
HS-10342 - Drug Profile
Product Description
Mechanism Of Action
History of Events
JS-101 - Drug Profile
Product Description
Mechanism Of Action
JS-104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lerociclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
milciclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
NUV-422 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ON-108110 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ON-123300 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OQL-051 - Drug Profile
Product Description
Mechanism Of Action
History of Events
palbociclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
PF-07220060 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PRT-3645 - Drug Profile
Product Description
Mechanism Of Action
RGT-419B - Drug Profile
Product Description
Mechanism Of Action
ribociclib succite - Drug Profile
Product Description
Mechanism Of Action
History of Events
RMC-4550 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RP-13XXX - Drug Profile
Product Description
Mechanism Of Action
SCR-8079 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit CDK4 and CDK6 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit CDK4/6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Target AR, CDK4 and CDK6 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit CDK4 for Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CDK4 for Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
Product Description
Mechanism Of Action
History of Events
SRX-3177 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TQ-05510 - Drug Profile
Product Description
Mechanism Of Action
TQB-3616 - Drug Profile
Product Description
Mechanism Of Action
History of Events
trilaciclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
TVT-227 - Drug Profile
Product Description
Mechanism Of Action
TVT-243 - Drug Profile
Product Description
Mechanism Of Action
TVT-287 - Drug Profile
Product Description
Mechanism Of Action
TY-302 - Drug Profile
Product Description
Mechanism Of Action
voruciclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
VS-2370 - Drug Profile
Product Description
Mechanism Of Action
History of Events
XH-30002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
XZP-3287 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Mar 19, 2022: Drug combition shows effectiveness in patients with recurrent ER-positive endometrial cancer
Mar 10, 2022: NEJM publication of Novartis Kisqali data shows longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Mar 10, 2022: EMA recommends extension of therapeutic indications for Abemaciclib
Mar 08, 2022: OnQuality Pharmaceuticals to present preclinical data for OQL-051, a novel chemotherapy-induced diarrhea therapeutic, at AACR
Mar 08, 2022: Lilly announces to present data from Verzenio at 2022 American Association for Cancer Research (AACR)
Feb 24, 2022: Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer
Jan 27, 2022: Health Cada authorizes Verzenio (abemaciclib) as the first and only CDK4/6 inhibitor for patients with HR+ HER2- high risk early breast cancer
Jan 19, 2022: Shanghai Fosun Pharmaceutical: Announcement in relation to the progress of drug clinical trial by a subsidiary
Jan 03, 2022: Hengrui Medicine’s class 1 new drug Isethiote Dalsili Tablets approved for marketing
Dec 28, 2021: Regor Therapeutics announces U.S. FDA authorization to conduct Regor’s first-in-human clinical trial with the next generation targeted inhibitor RGT-419B for oncology
Dec 22, 2021: Simcere Pharmaceutical Group: Voluntary announcement in relation to the inclusion of Trilaciclib for injection as a priority review drug by CDE
Dec 16, 2021: G1 Therapeutics announces expansion of COSELA (Trilaciclib) sales force
Dec 15, 2021: Nuvation Bio receives FDA Fast Track Desigtion for NUV-422 for the treatment of high-grade gliomas, including glioblastoma multiforme
Dec 13, 2021: Nuvation Bio announces FDA Clearance of investigatiol new drug application for NUV-422 for the Treatment of Prostate Cancer
Dec 09, 2021: ESMO: Two years of adjuvant Palbociclib added to endocrine therapy does not improve outcomes in early breast cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Indications, 2022 (Contd..3)
Number of Products under Development by Indications, 2022 (Contd..4)
Number of Products under Development by Indications, 2022 (Contd..5)
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Companies, 2022 (Contd..7)
Products under Development by Companies, 2022 (Contd..8)
Products under Development by Companies, 2022 (Contd..9)
Products under Development by Companies, 2022 (Contd..10)
Products under Development by Companies, 2022 (Contd..11)
Products under Development by Companies, 2022 (Contd..12)
Products under Development by Companies, 2022 (Contd..13)
Products under Development by Companies, 2022 (Contd..14)
Products under Development by Companies, 2022 (Contd..15)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Aucentra Therapeutics Pty Ltd, 2022
Pipeline by Beta Pharma Inc, 2022
Pipeline by Betta Pharmaceuticals Co Ltd, 2022
Pipeline by Cothera Bioscience Pty Ltd, 2022
Pipeline by CStone Pharmaceuticals Co Ltd, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by ESSA Pharma Inc, 2022
Pipeline by Fochon Pharmaceutical Ltd, 2022
Pipeline by G1 Therapeutics Inc, 2022
Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2022
Pipeline by HEC Pharma Co Ltd, 2022
Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2022
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Pipeline by MEI Pharma Inc, 2022
Pipeline by Novartis AG, 2022
Pipeline by Nuvation Bio Inc, 2022
Pipeline by Onconova Therapeutics Inc, 2022
Pipeline by OnQuality Pharmaceuticals LLC, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Prelude Therapeutics Inc, 2022
Pipeline by Qilu Regor Therapeutics Inc, 2022
Pipeline by Rhizen Pharmaceuticals SA, 2022
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022
Pipeline by Sanofi, 2022
Pipeline by SATT Conectus Alsace SAS, 2022
Pipeline by Shanghai Haihe Biopharma Co Ltd, 2022
Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, 2022
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
Pipeline by Shanghai Xunhe Pharmaceutical Technology Co Ltd, 2022
Pipeline by Shengke Pharmaceuticals (Jiangsu) Ltd, 2022
Pipeline by SignalRx Pharmaceuticals Inc, 2022
Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, 2022
Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Pipeline by Sino Biopharmaceutical Ltd, 2022
Pipeline by Tetranov International Inc, 2022
Pipeline by Tiziana Life Sciences Plc, 2022
Pipeline by Travecta Therapeutics Inc, 2022
Pipeline by ViroStatics SRL, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022